Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Athens, Greece.
J Oral Pathol Med. 2013 Feb;42(2):154-61. doi: 10.1111/j.1600-0714.2012.01190.x. Epub 2012 Jul 2.
BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in head and neck squamous cell carcinoma (HNSCC). We have recently shown that BCL2L12 mRNA expression is an unfavorable prognostic indicator in nasopharyngeal carcinoma (NPC) and that BCL2L12 can be regarded as a novel, useful tissue biomarker for the prediction of NPC patients' short-term relapse. The aim of this study was to analyze the mRNA expression of the novel apoptosis-related gene BCL2L12 in patients with HNSCC.
Total RNA was isolated from 53 malignant tumors originating in larynx, pharynx, tongue, buccal mucosa, parotid glands, and nasal cavity, as well as from 34 adjacent non-cancerous tissue specimens, resected from patients with HNSCC. A highly sensitive real-time PCR method for BCL2L12 mRNA quantification in head and neck tissues was developed using the SYBR(®) Green chemistry. After preparing cDNA by reverse transcription, relative quantification was performed using the comparative C(T) () method.
BCL2L12 mRNA levels were lower in laryngeal tumors of advanced tumor, node, metastasis (TNM) stage or bigger size and in well-differentiated malignant tongue neoplasms, compared with early-stage laryngeal tumors or poorly differentiated tongue tumors. Interestingly, the BCL2L12 expression showed significant discriminatory value, distinguishing efficiently patients with tongue squamous cell carcinoma (SCC) from non-cancerous population.
This is the first study examining the BCL2L12 mRNA expression in HNSCC. Our results suggest that BCL2L12 mRNA expression may serve as a potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute the great majority of HNSCC cases worldwide.
BCL2L12 是最近发现的一种基因,属于 BCL2 家族,该家族成员与头颈部鳞状细胞癌(HNSCC)有关。我们最近表明,BCL2L12 mRNA 的表达是鼻咽癌(NPC)的一个不利预后指标,BCL2L12 可以被视为 NPC 患者短期复发预测的一种新的有用组织生物标志物。本研究旨在分析新型凋亡相关基因 BCL2L12 在 HNSCC 患者中的 mRNA 表达。
从 53 例起源于喉、咽、舌、颊黏膜、腮腺和鼻腔的恶性肿瘤以及 34 例 HNSCC 患者的相应非癌组织中分离总 RNA。使用 SYBR(®)Green 化学法开发了一种用于头颈部组织 BCL2L12 mRNA 定量的高灵敏度实时 PCR 方法。通过反转录制备 cDNA 后,使用比较 C(T)()法进行相对定量。
与早期喉肿瘤或低分化舌肿瘤相比,晚期 TNM 分期或更大肿瘤大小的喉肿瘤以及分化良好的恶性舌肿瘤中的 BCL2L12 mRNA 水平较低。有趣的是,BCL2L12 表达显示出显著的区分价值,能够有效地将舌鳞状细胞癌(SCC)患者与非癌人群区分开来。
这是首次研究 BCL2L12 在 HNSCC 中的 mRNA 表达。我们的结果表明,BCL2L12 mRNA 表达可能作为舌和/或喉 SCC 的潜在预后生物标志物,而舌和/或喉 SCC 主要构成了全球绝大多数 HNSCC 病例。